Nuvation Bio price target lowered to $7 from $8 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Nuvation Bio to $7 from $8 and keeps a Buy rating on the shares. The firm says the pooled TRUST-I and TRUST-II results support FDA approval. However, it trimmed the price target to reflect Nuvation’s higher spending.